ACRSAclaris Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $5.32 · now $5.32 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, ACRS has typically landed between $3.75 and $7.04 — a range of −29.5% to +32.3% from the issuance price $5.32.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

2,727 overlapping 1 month windows · 2015-10-06 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($5.32) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ACRS has typically landed a month from the 2026-09-16 close of $5.32 — the range is history, not a prediction.

$3.75worst · -29.5%$7.04best · +32.3%
  • now $5.32 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $5.41 (+1.7%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $4.72–$6.1
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $3.75–$7.04
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,727 windows spanning 2015-10-06 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2023-10-13−87.2%−87.2%+4.5%
2023-10-16−85.6%−87.8%+0.0%
2023-10-17−84.0%−87.7%+0.0%
3 best
2021-01-13+308.4%+0.0%+313.1%
2021-01-12+298.2%−3.6%+298.2%
2021-01-14+291.1%−3.6%+296.9%

2,727 overlapping windows · 2015-10-06 – 2026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~11 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
36%
+14.6%
n=11
Feb
36%
−3.9%
n=11
Mar
45%
−2.2%
n=11
Apr
45%
+0.5%
n=11
May
55%
−3.5%
n=11
Jun
64%
+1.0%
n=11
Jul
55%
+0.8%
n=11
Aug
55%
−0.3%
n=11
Sep
36%
+1.3%
n=11
Oct
40%
+13.2%
n=10
Nov
36%
+7.5%
n=11
Dec
73%
+9.2%
n=11

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$7$22026-04-23: 1 insider sale, $1.4M — Leonard Braden Michael2026-04: 1 open-market sale, $1.4M↑ buys↓ salestenPercentOwner Leonard Braden Michael — Sale on 2026-04-23, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-04-23Leonard Braden MichaeltenPercentOwnerSale300,000 @ $4.53$1.4M−2.1% of holding−5.9%not yet — horizon still open13,950,000Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

239 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-01Kolbeck Roland WilhelmofficerWithheld for tax12,38523,990Form 4
2026-08-01Kolbeck Roland WilhelmofficerOption exercise36,375109,125Form 4
2026-08-01Kolbeck Roland WilhelmofficerOption exercise36,37536,375Form 4
2026-08-01Kolbeck Roland WilhelmofficerOption exercise36,37536,375Form 4
2026-06-05Molineaux Christopher P.directorOption exercise11,5800Form 4
2026-06-05MILANO VINCENTdirectorOption exercise11,5800Form 4
2026-06-05SCHIFF ANDREW NdirectorOption exercise11,5800Form 4
2026-06-05Mehra AnanddirectorOption exercise11,5800Form 4
2026-06-05Humphries William D.directorOption exercise11,5800Form 4
2026-06-05GOWEN MAXINEdirectorOption exercise11,5800Form 4
2026-06-05Mehra AnanddirectorOption exercise11,580726,403Form 4
2026-06-05Molineaux Christopher P.directorOption exercise11,58069,536Form 4
2026-06-05MILANO VINCENTdirectorOption exercise11,58028,896Form 4
2026-06-05Humphries William D.directorOption exercise11,58045,105Form 4
2026-06-05GOWEN MAXINEdirectorOption exercise11,58033,334Form 4
2026-06-05Humphries William D.directorOption exercise11,58045,105Form 4
2026-06-05MILANO VINCENTdirectorOption exercise11,58028,896Form 4
2026-06-05Mehra AnanddirectorOption exercise11,580726,403Form 4
2026-06-05Molineaux Christopher P.directorOption exercise11,58069,536Form 4
2026-06-05SCHIFF ANDREW NdirectorOption exercise11,58025,540Form 4
2026-06-05GOWEN MAXINEdirectorOption exercise11,58033,334Form 4
2026-06-05SCHIFF ANDREW NdirectorOption exercise11,58025,540Form 4
2026-06-04MILANO VINCENTdirectorAward / grant10,98710,987Form 4
2026-06-04SCHIFF ANDREW NdirectorAward / grant42,35042,350Form 4
2026-06-04SCHIFF ANDREW NdirectorAward / grant10,98710,987Form 4
2026-06-04MILANO VINCENTdirectorAward / grant42,35042,350Form 4
2026-06-04GOWEN MAXINEdirectorAward / grant42,35042,350Form 4
2026-06-04GOWEN MAXINEdirectorAward / grant10,98710,987Form 4
2026-06-04Mehra AnanddirectorAward / grant42,35042,350Form 4
2026-06-04Mehra AnanddirectorAward / grant10,98710,987Form 4
2026-06-04Molineaux Christopher P.directorAward / grant42,35042,350Form 4
2026-06-04Molineaux Christopher P.directorAward / grant10,98710,987Form 4
2026-06-04Humphries William D.directorAward / grant42,35042,350Form 4
2026-06-04Humphries William D.directorAward / grant10,98710,987Form 4
2026-05-01Hall Jesse WayneofficerWithheld for tax9,33027,045Form 4
2026-05-01Hall Jesse WayneofficerOption exercise36,375109,125Form 4
2026-05-01Hall Jesse WayneofficerOption exercise36,37536,375Form 4
2026-05-01Hall Jesse WayneofficerOption exercise36,37536,375Form 4
2026-03-01Balthaser KevinofficerWithheld for tax677187,453Form 4
2026-03-01Balthaser KevinofficerOption exercise2,3750Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.